MTOR and acute myeloid leukemia: Our experimental studies show that patients are heterogeneous with regard to the constitutive AML cell activation of the PI3K-Akt-mTOR pathway; this heterogeneity is increased by insulin and maintained in the presence of pathway inhibitors.